0001564590-22-013623.txt : 20220506 0001564590-22-013623.hdr.sgml : 20220506 20220405215517 ACCESSION NUMBER: 0001564590-22-013623 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-731-8389 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 CORRESP 1 filename1.htm life-corresp.DOCX.htm

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite 250

San Diego, California 92121

 

 

April 5, 2022

 

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Dorrie Yale

 

Re:

aTyr Pharma, Inc.

 

Registration Statement on Form S-3 (File No. 333-263585)

 

Request for Acceleration of Effective Date

              

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, aTyr Pharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on April 8, 2022, or as soon thereafter as possible, or such , or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Charles J. Bair and Alexa M. Ekman of Cooley LLP to make such a request on its behalf.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Alexa M. Ekman of Cooley LLP at (858) 550-6183 or aekman@cooley.com.

 

Sincerely,

 

aTyr Pharma, Inc.

 

 

 

By:

 

/s/ Jill M. Broadfoot

 

 

Jill M. Broadfoot

 

 

Chief Financial Officer